RxDoctor Payments DataLook up a doctor →

Kurtis Woolf, MD

Family Medicine · Layton, UTNPI 1528140878

Payments from drug & device makers

$223,628in general payments, 2019–2025

Across 338 payments — averaging $661.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Diasorin Molecular LLC$218K
  • AbbVie$2K
  • Pfizer$332
  • Merck$278
  • GSK$243
  • Astellas Pharma US Inc$228
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$5,287100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$223,628 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$114,102
Medicare patients
199
Services billed
3,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol95$96,861
TrulicityDulaglutide64$96,128
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$74,353
EliquisApixaban49$54,837
XareltoRivaroxaban48$52,696
OzempicSemaglutide45$47,546
JanuviaSitagliptin Phosphate34$34,971
MounjaroTirzepatide18$32,114
JardianceEmpagliflozin19$23,676
VraylarCariprazine Hcl11$16,297
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$13,139
Humalog Kwikpen U-200Insulin Lispro12$12,573
SymbicortBudesonide/Formoterol Fumarate21$10,155
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$7,924
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$6,318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$158$128,24282 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$192$120,156130 claims
GSKTrelegy Ellipta, Incruse Ellipta$243$78,76873 claims
PfizerEliquis$332$54,83749 claims
Johnson & JohnsonXarelto$183$52,69648 claims
Novo NordiskOzempic$30$47,54645 claims
MerckJanuvia$278$34,97134 claims
Boehringer IngelheimJardiance$63$23,67619 claims
AbbVieVraylar$1,828$16,29711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 928 family medicine providers in Utah.

Other family medicine in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →